Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. [electronic resource]
Producer: 20141216Description: 1030-6 p. digitalISSN:- 1096-8652
- Aminopyridines -- pharmacology
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Cell Adhesion -- drug effects
- Cell Cycle -- drug effects
- Cell Line
- Cell Line, Tumor
- Chemotaxis -- drug effects
- Coculture Techniques
- Drug Screening Assays, Antitumor
- Female
- Fibronectins
- Humans
- Mesenchymal Stem Cells -- cytology
- Mice
- Mice, SCID
- Morpholines -- pharmacology
- Multiple Myeloma -- enzymology
- Neoplasm Invasiveness
- Neoplasm Proteins -- antagonists & inhibitors
- Phosphoinositide-3 Kinase Inhibitors
- Protein Kinase Inhibitors -- pharmacology
- RNA Interference
- RNA, Small Interfering -- pharmacology
- Receptors, CXCR4 -- biosynthesis
- Waldenstrom Macroglobulinemia -- enzymology
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.